• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Looking Into Gelesis Holdings's Return On Capital Employed

    3/29/23 10:47:29 AM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GLS alert in real time by email

    Gelesis Holdings (NYSE:GLS) brought in sales totaling $2.63 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 65.49%, resulting in a loss of $23.41 million. Gelesis Holdings collected $6.65 million in revenue during Q3, but reported earnings showed a $14.15 million loss.

    What Is Return On Capital Employed?

    Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Gelesis Holdings posted an ROCE of 1.9%.

    Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

    ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Gelesis Holdings is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

    For Gelesis Holdings, the positive return on capital employed ratio of 1.9% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

    Analyst Predictions

    Gelesis Holdings reported Q4 earnings per share at $-0.33/share, which did not meet analyst predictions of $-0.26/share.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $GLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

    MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

    4/3/23 4:05:00 PM ET
    $GLS
    $PEAR
    $SGHT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Gelesis Reports Fourth Quarter and Full Year 2022 Results

     Gelesis has demonstrated strong demand for Plenity, helping over 200,000 people on their weight loss journeys since launch Company has filed with FDA to make Plenity available to Over the Counter (OTC), which should significantly broaden consumer access and reduce the cost to reach new members Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the year ended December 31, 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love. Plenity

    3/28/23 7:00:00 AM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gelesis to Participate in the 25th Annual ICR Conference

    Gelesis (NYSE:GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on Monday, January 9, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005182/en/Gelesis is the maker of Plenity, an FDA-cleared weight management product. (Graphic: Business Wire) Gelesis will host a presentation at 1:30 p.m. ET. The live webcast can be accessed on the "Events & Presentations" section of the Gelesis Investor Relations website at https://ir.gelesis.com/. The webcast will also be archived and available for replay. About Gelesis Gelesis H

    1/5/23 7:00:00 AM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Puretech Health Plc

    4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

    9/21/23 4:30:07 PM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Puretech Health Plc

    4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

    6/14/23 4:30:15 PM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Puretech Health Plc

    4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

    5/31/23 5:30:09 PM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GLS
    SEC Filings

    View All

    Gelesis Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update, Financial Statements and Exhibits

    8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

    10/30/23 8:58:39 PM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form CT ORDER filed by Gelesis Holdings Inc.

    CT ORDER - GELESIS HOLDINGS, INC. (0001805087) (Filer)

    10/19/23 2:14:03 PM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gelesis Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

    10/16/23 4:15:09 PM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GLS
    Leadership Updates

    Live Leadership Updates

    View All

    Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

    MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

    4/3/23 4:05:00 PM ET
    $GLS
    $PEAR
    $SGHT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $GLS
    Financials

    Live finance-specific insights

    View All

    Gelesis Reports Fourth Quarter and Full Year 2022 Results

     Gelesis has demonstrated strong demand for Plenity, helping over 200,000 people on their weight loss journeys since launch Company has filed with FDA to make Plenity available to Over the Counter (OTC), which should significantly broaden consumer access and reduce the cost to reach new members Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the year ended December 31, 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love. Plenity

    3/28/23 7:00:00 AM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gelesis Reports Third Quarter 2022 Results

    Plenity quarterly product revenue increased 114% year-over-year to $6.4 million, with 23,500 new members and 92,000 units sold in Q3 Quarterly gross profit increased by $2.6 million year-over-year, with gross margin improving from 8% to 44% Company is preparing to submit Plenity for Over the Counter (OTC) status, which would make it available without the need for a prescription and further reduce cost of customer acquisition Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the third quarter of 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people

    11/14/22 7:00:00 AM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

    Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity® for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open. Gelesis management will host a live conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221107005166/en/Gelesis is a consumer-centered biotherapeutics company and the maker of Plenity for weight management. (Photo: Business Wire) The live call can be accessed via webcast on the "Events & Pr

    11/7/22 7:00:00 AM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)

    SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

    10/16/23 4:31:26 PM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)

    SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

    9/21/23 4:30:30 PM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)

    SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

    6/29/23 4:30:27 PM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care